Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer
AssigneeBold Therapeutics, Inc.
InventorsSuzanne Bakewell, Jyothi Sethuraman
Life of this patent
Estimating the term…
Abstract
IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
Claims10
A method for treating an adenocarcinoma in a patient in need thereof comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with gemcitabine, and wherein the administration of IT-139, or a pharmaceutically acceptable composition thereof, results in a reduction in an amount of GRP78 as compared to administration of gemcitabine alone.
Dependencies are inferred from the claim text.